Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Recent Applications of Chitosan-Based Biomaterials as Wound Dressings

Jin SG.

Clinical Trial on Chronic Wound, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Mol Sci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41751771
PMCID
PMC12941076
DOI
10.3390/ijms27041637
Citations
4

Abstract (original English)

Chitosan is a natural biopolymer for advanced wound healing due to its antimicrobial activity, biocompatibility, and hemostatic properties. However, its clinical utility is limited by its low solubility and poor mechanical properties. This review summarizes recent strategies that have successfully overcome these shortcomings, focusing on the development of multifunctional chitosan hybrid dressings. These dressings, which include hydrogels, hydrocolloids, films, sponges, and scaffolds, are now being fabricated using advanced systems like electrospinning, 3D printing, microneedle (MN), and nanocomposites technologies to maximize wound healing efficacy. Specifically, modification techniques used to overcome chitosan's shortcomings include: (1) chemical derivatization to enhance solubility, (2) polymer hybridization with natural and synthetic materials to enhance mechanical properties, and (3) functionalization with active ingredients. These materials, including metal/inorganic nanoparticles, natural compounds, and amino acids, are added to maximize therapeutic efficacy. In conclusion, chitosan hybrid materials and dressings provide an excellent foundation for next-generation wound dressings. However, overcoming challenges associated with material diversity and establishing standardized manufacturing processes and clinical trials remain critical for successful commercialization.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsHumansChitosanBiocompatible MaterialsHydrogelsBandagesWound Healing

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research